BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/10/2025 6:13:58 AM | Browse: 17 | Download: 0
Publication Name World Journal of Clinical Oncology
Manuscript ID 108768
Country China
Category Medicine, Research & Experimental
Manuscript Type Editorial
Article Title Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies
Manuscript Source Invited Manuscript
All Author List Shuai Xiao, Xiao-Zhen Xu, Meng Liao, Dan-Dan Song, Jing-Feng Tang and Ce-Fan Zhou
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 32270768
National Natural Science Foundation of China 82273970
National Natural Science Foundation of China 32070726
National Natural Science Foundation of China 82370715
Hubei Natural Science Foundation of China 2024AFB218
National Key R&D Program of China 2023YFC2507904
Doctoral Start-up Foundation of Hubei University of Technology XJ2022003901
Corresponding Author Ce-Fan Zhou, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Key Words Histone deacetylase inhibitors; Trichostatin A; Combination therapeutics; Selective inhibitors; Multidrug resistance
Core Tip Histone deacetylase inhibitors (HDACis) have been extensively researched for their potential anticancer effects. However, in addition to their role in inhibiting tumor growth, it has also surprisingly facilitated the metastasis of esophageal squamous cell carcinoma. Clinical studies indicate that the effectiveness of HDACis in treating solid tumors often falls short of expectations, and these inhibitors may inherently carry certain risks. In this article, we examine the potential dangers associated with the clinical use of HDACis, including severe adverse effects, off-target toxicities, multidrug resistance, and limited efficiency in solid tumors. Furthermore, future research should focus on combination therapies, the development of selective or dual-target inhibitors to mitigate the adverse effects of HDACis treatments.
Citation Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF. Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. World J Clin Oncol 2025; In press
Received
2025-04-23 04:11
Peer-Review Started
2025-04-23 04:12
To Make the First Decision
Return for Revision
2025-05-14 06:04
Revised
2025-05-21 06:33
Second Decision
2025-07-10 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-07-10 06:13
Articles in Press
2025-07-10 06:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com